A trial looking at CYC202 for solid tumours

Cancer type:

All cancer types




Phase 1

This trial was looking at a new drug called CYC202 to treat solid tumours. A solid tumour is any cancer apart from leukaemia or lymphoma. This trial was supported by Cancer Research UK.

There are substances inside cancer cells called enzymes. These are important for cell growth. CYC202 can stop enzymes working. If the enzymes don’t work, the cell cannot divide and grow. The researchers hoped that CYC202 would be able to stop the growth of cancer cells.

The aims of the trial were to

  • Find a safe dose of CYC202
  • Learn more about the side effects

Summary of results

The researchers learnt more about CYC202 and the effects of different doses, but the cancer did not get smaller in any of the people in this trial.

The trial recruited 21 people. The first few patients had a very low dose of CYC202. As they didn’t have any bad side effects, the next few people had a higher dose, and so on, for 3 different doses. At least 3 people safely had each dose before the dose was increased. By doing this, the researchers were able to work out the highest dose they could use without causing bad side effects.

The most common side effect that people did have was sickness, but this could be controlled with anti sickness tablets. Other side effects included tiredness (fatigue), loss of appetite and temporary kidney problems.

The researchers also looked at the effect CYC202 had on the cancer. They found that

  • In 8 people, the cancer stayed the same size – researchers call this stable disease Open a glossary item
  • In the other 13 people, the cancer continued to grow

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Ian Judson

Supported by

Cancer Research UK (Centre for Drug Development)
Cycacel Ltd

Other information

This is Cancer Research UK trial number CRUKD/01/019.

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 25

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think